3 VC-Backed Drugmakers Fire Up $200M In IPO Plans
Monday was a busy day for venture capital-backed biopharmaceutical companies eyeing initial public offerings, as three California-based drugmakers — targeting difficult-to-treat infections, osteoarthritis joint pain and immuno-oncology therapies — set terms...To view the full article, register now.
Already a subscriber? Click here to view full article